By Colin Kellaher

Roche Holdings AG's (ROG.EB) Genentech unit Friday said a phase 3 study of Tecentriq plus Cotellic and Zelboraf met its primary endpoint of progression-free survival in a form of the skin cancer melanoma.

Genentech said the study showed adding Tecentriq to Cotellic and Zelboraf helped to reduce the risk of disease worsening or death in people with previously untreated BRAF V600 mutation-positive advanced melanoma compared to placebo plus Cotellic and Zelboraf.

The company said the safety profile observed in the study was consistent with the known safety profiles of the individual drugs, adding that it plans to discuss the results with health authorities, including the U.S. Food and Drug Administration and European Medicines Agency.

Exelixis Inc. (EXEL) discovered Cotellic and is collaborating on the development of the drug with Genentech as part of a 2006 agreement.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 13, 2019 07:22 ET (12:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.